Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1996; 27:1-7
© 1996 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berger, P.
Right arrow Articles by Faxon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berger, P.
Right arrow Articles by Faxon, D.

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR)

PB Berger, DR Holmes Jr, EM Ohman, MA O'Hanesian, JG Murphy, RS Schwartz, PW Serruys, and DP Faxon

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.

OBJECTIVES. This study sought to compare the frequency of restenosis, reocclusion and adverse cardiovascular events after angioplasty of occluded versus nonoccluded coronary arteries. BACKGROUND. Angioplasty of chronically occluded coronary arteries is believed to be associated with a higher frequency of restenosis and reocclusion than angioplasty of subtotal stenoses. Whether this leads to adverse cardiovascular events is unknown. METHODS. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Restenosis (MARCATOR) was a placebo-controlled trial with angiographic follow-up to determine the effect of the angiotensin-converting enzyme inhibitor cilazapril on the frequency of restenosis. In this trial, restenosis was defined as 1) angiographic reduction of minimal lumen diameter > or = 0.72 mm between angioplasty and the follow-up visit; and 2) > 50% diameter stenosis on the follow-up angiogram. We identified 139 patients with successful angioplasty of a coronary occlusion (Group 1) and compared the frequency of restenosis, reocclusion and adverse cardiovascular events with that in 1,295 patients with successful angioplasty of a subtotal stenosis (Group 2). RESULTS. Restenosis occurred in 36 patients with occluded arteries (29%) versus 264 with nonoccluded arteries (23%, p = 0.177) by definition 1 and in 62 patients with occluded arteries (49%) versus 478 with nonoccluded arteries (42%, p = 0.119) by definition 2. Occlusion was present in 24 Group 1 patients (19%) compared with 74 Group 2 patients (7%) (p < 0.001). During the 6 month follow-up period, two Group 1 patients (1.4%) and six Group 2 patients (0.5%) died; no Group 1 patients and 10 Group 2 patients (0.8%) developed severe congestive heart failure; nonfatal myocardial infarction occurred in 4 Group 1 patients (2.9%) and 31 Group 2 patients (2.4%); repeat coronary angioplasty or bypass surgery was performed in 29 Group 1 patients (21%) and 232 Group 2 patients (18%); and angina was present in 18 Group 1 and 163 Group 2 patients (13% for both). Eighty-six Group 1 patients (62%) and 853 Group 2 patients (66%) remained free of these adverse events during the 6-month follow-up period (p = 0.513). CONCLUSIONS. The frequency of restenosis was slightly but not significantly greater after successful angioplasty of an occluded artery than after angioplasty of a subtotal stenosis. Although reocclusion was more frequent, occurring in 19% of patients, the net clinical benefit of angioplasty in such patients was similar to that in patients with subtotal stenoses over the 6-month follow-up period.


This article has been cited by other articles:


Home page
HeartHome page
S Aziz and D R Ramsdale
Chronic total occlusions--a stiff challenge requiring a major breakthrough: is there light at the end of the tunnel?
Heart, June 1, 2005; 91(suppl_3): iii42 - iii48.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. S. Schwartz, N. A. Chronos, and R. Virmani
Preclinical restenosis models and drug-eluting stents: Still important, still much to learn
J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Z. Olivari, P. Rubartelli, F. Piscione, F. Ettori, A. Fontanelli, L. Salemme, C. Giachero, C. Di Mario, G. Gabrielli, L. Spedicato, et al.
Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE)
J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1672 - 1678.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. Chan
Review: Developments in restenosis
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 145 - 149.
[Abstract] [PDF]


Home page
Eur Heart JHome page
C Lotan, Y Rozenman, A Hendler, Y Turgeman, O Ayzenberg, R Beyar, R Krakover, T Rosenfeld, and M.S Gotsman
Stents in Total Occlusion for restenosis Prevention. The multicentre randomized STOP study
Eur. Heart J., December 1, 2000; 21(23): 1960 - 1966.
[Abstract] [PDF]


Home page
Eur Heart JHome page
A. Kleemann, S. Eckert, A. von Eckardstein, W. Lepper, U. Schernikau, U. Gleichmann, P. Hanrath, E. Fleck, A. Neiss, S. Kerber, et al.
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT)
Eur. Heart J., October 1, 1999; 20(19): 1393 - 1406.
[Abstract] [PDF]


Home page
Eur Heart JHome page
B. Meier
The stent, the Procrustes for chronic total coronary occlusions?
Eur. Heart J., August 2, 1999; 20(16): 1142 - 1144.
[PDF]


Home page
Eur Heart JHome page
J. Schofer, T. Rau, M. Schluter, and D.G. Mathey
Restenosis after stenting of matched occluded and non-occluded coronary arteries. Should there be a difference?
Eur. Heart J., August 2, 1999; 20(16): 1175 - 1181.
[Abstract] [PDF]


Home page
HeartHome page
F Fath-Ordoubadi, K J Beatt, N Spyrou, and P G Camici
Efficacy of coronary angioplasty for the treatment of hibernating myocardium
Heart, August 1, 1999; 82(2): 210 - 216.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. R. Holmes Jr., J. Hirshfeld Jr., D. Faxon, R. Vlietstra, A. Jacobs, S. B. King III, T. M. Bashore, N. D. Bridges, C. B. Higgins, L. F. Hiratzka, et al.
ACC expert consensus document on coronary artery stents: Document of the American College of Cardiology
J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1471 - 1482.
[Full Text] [PDF]


Home page
NeurologyHome page
R. G. Hart, D. G. Sherman, J. D. Easton, and J. A. Cairns
Prevention of stroke in patients with nonvalvular atrial fibrillation
Neurology, September 1, 1998; 51(3): 674 - 681.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Rubartelli, L. Niccoli, E. Verna, C. Giachero, M. Zimarino, A. Fontanelli, C. Vassanelli, L. Campolo, E. Martuscelli, G. Tommasini, et al.
Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial
J. Am. Coll. Cardiol., July 1, 1998; 32(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Lafont and D. Faxon
Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials?
Cardiovasc Res, July 1, 1998; 39(1): 50 - 59.
[Full Text] [PDF]


Home page
NeurologyHome page
T. Taivassalo, N. De Stefano, Z. Argov, P. M. Matthews, J. Chen, A. Genge, G. Karpati, and D. L. Arnold
Effects of aerobic training in patients with mitochondrial myopathies
Neurology, April 1, 1998; 50(4): 1055 - 1060.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. Kosinski and B. P. Grubb
Clinical neuromythology XV. Feinting science
Neurology, September 1, 1997; 49(3): 902 - 902.
[Full Text] [PDF]


Home page
NeurologyHome page
D. G. Benditt
Clinical neuromythology XV. Feinting science
Neurology, September 1, 1997; 49(3): 901 - 902.
[Full Text] [PDF]


Home page
NeurologyHome page
W. M. Landau and D. A. Nelson
Clinical neuromythology XV. Feinting science
Neurology, September 1, 1997; 49(3): 902 - 904.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement